In 2005, Eric et al., proposed to use “Type 3 diabetes” to reflect the abnormal changes in the levels of insulin, insulin-like growth factor (IGF) I/II, insulin receptor (IR), and insulin receptor substrate (IRS) in the brains of AD patients [34]. The gene discussed is INS; the disease is Alzheimer disease.